Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.

The study of melanocyte biology is important to understand their role in health and disease. However, current methods of gene transfer into melanocytes are limited by safety or efficacy. Recombinant adeno-associated virus (rAAV) has been extensively investigated as a gene therapy vector, is safe and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hilary M Sheppard, James E Ussher, Daniel Verdon, Jennifer Chen, John A Taylor, P Rod Dunbar
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e972f4073f5643dea0cd96d0ba80ba96
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e972f4073f5643dea0cd96d0ba80ba96
record_format	dspace
spelling	oai:doaj.org-article:e972f4073f5643dea0cd96d0ba80ba962021-11-18T07:47:23ZRecombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.1932-620310.1371/journal.pone.0062753https://doaj.org/article/e972f4073f5643dea0cd96d0ba80ba962013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23646140/?tool=EBIhttps://doaj.org/toc/1932-6203The study of melanocyte biology is important to understand their role in health and disease. However, current methods of gene transfer into melanocytes are limited by safety or efficacy. Recombinant adeno-associated virus (rAAV) has been extensively investigated as a gene therapy vector, is safe and is associated with persistent transgene expression without genome integration. There are twelve serotypes and many capsid variants of rAAV. However, a comparative study to determine which rAAV is most efficient at transducing primary human melanocytes has not been conducted. We therefore sought to determine the optimum rAAV variant for use in the in vitro transduction of primary human melanocytes, which could also be informative to future in vivo studies. We have screened eight variants of rAAV for their ability to transduce primary human melanocytes and identified rAAV6 as the optimal serotype, transducing 7-78% of cells. No increase in transduction was seen with rAAV6 tyrosine capsid mutants. The number of cells expressing the transgene peaked at 6-12 days post-infection, and transduced cells were still detectable at day 28. Therefore rAAV6 should be considered as a non-integrating vector for the transduction of primary human melanocytes.Hilary M SheppardJames E UssherDaniel VerdonJennifer ChenJohn A TaylorP Rod DunbarPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 4, p e62753 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hilary M Sheppard James E Ussher Daniel Verdon Jennifer Chen John A Taylor P Rod Dunbar Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.
description	The study of melanocyte biology is important to understand their role in health and disease. However, current methods of gene transfer into melanocytes are limited by safety or efficacy. Recombinant adeno-associated virus (rAAV) has been extensively investigated as a gene therapy vector, is safe and is associated with persistent transgene expression without genome integration. There are twelve serotypes and many capsid variants of rAAV. However, a comparative study to determine which rAAV is most efficient at transducing primary human melanocytes has not been conducted. We therefore sought to determine the optimum rAAV variant for use in the in vitro transduction of primary human melanocytes, which could also be informative to future in vivo studies. We have screened eight variants of rAAV for their ability to transduce primary human melanocytes and identified rAAV6 as the optimal serotype, transducing 7-78% of cells. No increase in transduction was seen with rAAV6 tyrosine capsid mutants. The number of cells expressing the transgene peaked at 6-12 days post-infection, and transduced cells were still detectable at day 28. Therefore rAAV6 should be considered as a non-integrating vector for the transduction of primary human melanocytes.
format	article
author	Hilary M Sheppard James E Ussher Daniel Verdon Jennifer Chen John A Taylor P Rod Dunbar
author_facet	Hilary M Sheppard James E Ussher Daniel Verdon Jennifer Chen John A Taylor P Rod Dunbar
author_sort	Hilary M Sheppard
title	Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.
title_short	Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.
title_full	Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.
title_fullStr	Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.
title_full_unstemmed	Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.
title_sort	recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/e972f4073f5643dea0cd96d0ba80ba96
work_keys_str_mv	AT hilarymsheppard recombinantadenoassociatedvirusserotype6efficientlytransducesprimaryhumanmelanocytes AT jameseussher recombinantadenoassociatedvirusserotype6efficientlytransducesprimaryhumanmelanocytes AT danielverdon recombinantadenoassociatedvirusserotype6efficientlytransducesprimaryhumanmelanocytes AT jenniferchen recombinantadenoassociatedvirusserotype6efficientlytransducesprimaryhumanmelanocytes AT johnataylor recombinantadenoassociatedvirusserotype6efficientlytransducesprimaryhumanmelanocytes AT proddunbar recombinantadenoassociatedvirusserotype6efficientlytransducesprimaryhumanmelanocytes
_version_	1718423007859310592

Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.

Ejemplares similares